05.09.2022 • News

Technip Energies Buys DSM’s Biosuccinium Technology

French engineering and technology company Technip Energies has boosted its sustainable chemicals portfolio with the purchase of DSM’s biosuccinium technology. Financial terms were not disclosed.

Technip said it will be the only technology licensed on the market for producing bio-based succinic acid, which is a feedstock for manufacturing polybutylene succinate (PBS), a sustainable packaging material for food contact applications.

“This addition to our growing sustainable chemicals portfolio will allow Technip Energies to license a solution for the production of a bio-sourced and biodegradable polymer, which has a 50% lower carbon footprint compared to fossil-based routes,” said Bhaskar Patel, senior vice president, sustainable fuels, chemicals and circularity at Technip Energies. “Superior product properties, combined with best-in-class sustainability performance, are key attributes in today’s consumer market. We shall leverage the whole PBS value chain, where we already license the technology for the polymerization of the bio-sourced monomers into PBS.”

The purchase includes a wide range of patent families and proprietary yeast strains, which Technip said have been demonstrated in large-scale production facilities.

DSM originally developed biosuccinium as part of Reverdia, a joint venture with Roquette that was dissolved on Apr. 1, 2019. DSM retained exclusive licensing rights to the technology.

Author: Elaine Burridge, Freelance Author

© Shutterstock
© Shutterstock

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read